Cite
ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy
MLA
Peter Bailey, et al. ADAM12 Is a Circulating Marker for Stromal Activation in Pancreatic Cancer and Predicts Response to Chemotherapy. Nov. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2157ec8c528e05a77c053a34a9745600&authtype=sso&custid=ns315887.
APA
Peter Bailey, Maarten F. Bijlsma, Frederike Dijk, M.J. van de Vijver, Hanneke Wilmink, Andrew V. Biankin, R. Jiang, H.W.M. van Laarhoven, J. S. Li, Helene Damhofer, O.R.C. Busch, Cynthia Waasdorp, Daniel W. Pierce, Hemant M. Kocher, Marc G. Besselink, David K. Chang, Jan Paul Medema, Veronique L. Veenstra, & L.B. van Rijssen. (2018). ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy.
Chicago
Peter Bailey, Maarten F. Bijlsma, Frederike Dijk, M.J. van de Vijver, Hanneke Wilmink, Andrew V. Biankin, R. Jiang, et al. 2018. “ADAM12 Is a Circulating Marker for Stromal Activation in Pancreatic Cancer and Predicts Response to Chemotherapy,” November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2157ec8c528e05a77c053a34a9745600&authtype=sso&custid=ns315887.